Multi-omics profiles of chronic low back pain and fibromyalgia—Study protocol
Our study addresses the need for a better understanding of the molecular mechanisms underlying chronic low back pain and fibromyalgia. Using a multi-omics approach, we hope to identify converging evidence for potential targets of future therapeutic developments, as well as promising candidate biomarkers for further investigation by biomarker validation studies. We believe that accurate patient phenotyping will be essential for the discovery process, as both conditions are characterized by high heterogeneity and complexity, likely rendering molecular mechanisms phenotype specific.
Authors
- Catherine P. Chia
- Daniel Raftery (ORCID: https://orcid.org/0000-0003-2467-8118)
- Ava Ward
- Michele Curatolo (ORCID: https://orcid.org/0000-0003-4130-6826)
- Savera Khan
- Darrell A. Henze (ORCID: https://orcid.org/0000-0001-5168-8413)
- Rebecca M. Klein (ORCID: https://orcid.org/0000-0001-9638-3752)
- Abby P Chiu
- Wentao Zhu
- Sandra K. Johnston (ORCID: https://orcid.org/0000-0003-4106-3924)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- University of Washington Applied Physics Laboratory (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1371/journal.pone.0312061
- Citations
- 1
- Primary Topic
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Merck